A Phase 2 interventional study of Nivolumab and Relatlimab in Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer and Metastatic Non-small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 125 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb — 21 open to participants now, 35 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bristol-Myers Squibb.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 23rd largest by enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2021, is one of 32 in phase 2, and was the 81st registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 9 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
RayzeBio, Inc. · Sites in Australia, New Zealand, South Africa
Ages 18+
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 29 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 33 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 53 · Phase 3 29 · Phase 4 2
First in 2000; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 468 is above the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 169 across the 107 interventional studies, 404 across the 21 observational. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06140836Phase 3Bristol-Myers SquibbA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | 2027-02-16 |
| NCT05161325Bristol-Myers SquibbA Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT07671092RayzeBio, Inc.Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC | 2027-08 |
| NCT06544655Bristol-Myers SquibbA Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | 2027-10-14 |
Add all 6 to your calendar (.ics) → With an account.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Biological: Relatlimab · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Nab-Paclitaxel · Drug: Pemetrexed
Biological: Nivolumab · Biological: Relatlimab · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Nab-Paclitaxel · Drug: Pemetrexed
Biological: Nivolumab · Biological: Relatlimab · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Pemetrexed
Biological: Nivolumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Pemetrexed
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1
Percentage of participants with treatment related adverse events (TRAEs) leading to discontinuation within 12 weeks of first dose. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.
Time frame: from first dose to 12 weeks after first dose
ORR Per RECISTS v1.1 by BICR in Part 2
Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.
Time frame: Approximately 14.8 Months
TRAEs Leading to Discontinuation in Part 1
Number of participants with treatment related adverse events (TRAEs) leading to discontinuation based on grade. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0
Time frame: From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)
Number of Participants With a Treatment Related AEs in Part 1
Number of participants with a treatment related AE in part 1. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0
Time frame: From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)
Number of Participants With Treatment Releted SAEs in Part 1
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \[e.g., medical, surgical\] to prevent one of the other serious outcomes listed in the definition). Grading will be determined for severity according to the NCI CTCAE v5.0.
Time frame: From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)
Number of Participants With Treatment Releted Select AEs in Part 1
AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.
Time frame: From first dose to 30 days post last dose of study therapy (Approximately 32.8 Months)
ORR by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2
Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.
Time frame: Approximately 14.8 Months
DoR Per RECISTS v1.1 by BICR in Part 2
Duration of Response (DOR) will be assessed by BICR. It is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR (per RECIST v1.1), or death due to any cause, whichever occurs first.
Time frame: Approximately up to 13.7 months
Number of Participants With a AE in Part 2
Number of participants with an adverse event (AE). AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.
Time frame: From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)
Number of Participants With a Treatment Related AEs in Part 2
AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.
Time frame: From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)
Number of Participants With a Treatment Related SAEs in Part 2
SAE is defined as a life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe). SAEs can also result in death. The AE requires inpatient hospitalization or causes prolongation of existing hospitalization. Results in persistent or significant disability/incapacity. Is a congenital anomaly/birth defect. Is an important medical event (defined as a medical event(s) that may not be immediately lifethreatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \[e.g., medical, surgical\] to prevent one of the other serious outcomes listed in the definition above.) Grading will be determined for severity according to the NCI CTCAE v5.0.
Time frame: From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)
Number of Participants With Endocrine Immune-mediated Adverse Events in Part 2
IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. Grading will be determined for severity according to the NCI CTCAE v5.0.
Time frame: From first dose to 30 days post last dose of study therapy (Approximately 14.8 Months)
ORR by LAG-3 Expression Per RECISTS v1.1 by BICR in Part 2
Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.
Time frame: On Going
ORR by FG-L1 Expression Per RECISTS v1.1 by BICR in Part 2
Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.
Time frame: Ongoing
PFS Per RECISTS v1.1 by BICR in Part 2
Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.
Time frame: Ongoing
PFS by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2
Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.
Time frame: Ongoing
PFS by LAG-3 Expression Per RECISTS v1.1 by BICR in Part 2
Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.
Time frame: Ongoing
PFS by FG-L1 Expression Per RECISTS v1.1 by BICR in Part 2
Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.
Time frame: Ongoing
Number of Participants With Treatment Releted Select AEs in Part 2
AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.
Time frame: Ongoing
| Milestone | Part 1: Treatment A | Part 1: Treatment B | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|---|---|
| Started | 79 | 80 | 158 | 151 |
| Completed | 77 | 79 | 158 | 149 |
| Not completed | 2 | 1 | 0 | 2 |
| Withdrew: No longer meets study criteria | 2 | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 1 |
| Withdrew: Other reasons | 0 | 0 | 0 | 1 |
| Milestone | Part 1: Treatment A | Part 1: Treatment B | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|---|---|
| Started | 77 | 79 | 158 | 149 |
| Completed | 9 | 12 | 61 | 60 |
| Not completed | 68 | 67 | 97 | 89 |
| Withdrew: Participant withdrew consent | 4 | 0 | 1 | 2 |
| Withdrew: Death | 3 | 1 | 4 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 |
| Withdrew: Poor/non compliance | 0 | 0 | 1 | 0 |
| Withdrew: Participant no longer meets study criteria | 0 | 1 | 0 | 0 |
| Withdrew: Administrative reasons by sponsor | 3 | 2 | 0 | 0 |
| Withdrew: Other reasons | 2 | 0 | 1 | 1 |
| Withdrew: Disease progression | 40 | 35 | 63 | 63 |
| Withdrew: Study drug toxicity | 12 | 15 | 13 | 12 |
| Withdrew: Ae unrelated to study drug | 4 | 9 | 12 | 9 |
| Withdrew: Participant request to discontinue treatment | 0 | 2 | 2 | 0 |
Percentage of participants with treatment related adverse events (TRAEs) leading to discontinuation within 12 weeks of first dose. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.
| Percentage of Participants | Part 1: Treatment A | Part 1: Treatment B |
|---|---|---|
| TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1 | 5.6 (1.6 to 13.8) | 12.1 (5.4 to 22.5) |
Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.
| Percentage of Participants | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|
| ORR Per RECISTS v1.1 by BICR in Part 2 | 50.6 (43.8 to 57.4) | 43.0 (36.2 to 50.1) |
Number of participants with treatment related adverse events (TRAEs) leading to discontinuation based on grade. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0
| Participants | Part 1: Treatment A | Part 1: Treatment B |
|---|---|---|
| Any Grade | 21 | 18 |
| Grade 3 to 4 | 13 | 12 |
| Grade 5 | 1 | 0 |
Number of participants with a treatment related AE in part 1. AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0
| Participants | Part 1: Treatment A | Part 1: Treatment B |
|---|---|---|
| Number of Participants With a Treatment Related AEs in Part 1 | 75 | 76 |
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \[e.g., medical, surgical\] to prevent one of the other serious outcomes listed in the definition). Grading will be determined for severity according to the NCI CTCAE v5.0.
| Participants | Part 1: Treatment A | Part 1: Treatment B |
|---|---|---|
| Any Grade | 20 | 24 |
| Grade 3 to 4 | 14 | 18 |
| Grade 5 | 2 | 4 |
AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.
| Participants | Part 1: Treatment A | Part 1: Treatment B |
|---|---|---|
| Gastrointestinal | 18 | 15 |
| Hepatic | 26 | 18 |
| Pulmonary | 4 | 5 |
| Renal | 9 | 4 |
| Skin | 24 | 18 |
| Hypersensitivity/Infusion Reaction | 5 | 2 |
Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.
| Percentage of Participants | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|
| PD-L1 <1% | 48.6 (38.2 to 59.0) | 44.8 (34.4 to 55.5) |
| PD-L1 >= 1% | 53.2 (43.3 to 62.8) | 39.4 (29.7 to 49.9) |
| Not Quantifiable | 44.4 (16.9 to 74.9) | 53.8 (28.7 to 77.6) |
Duration of Response (DOR) will be assessed by BICR. It is defined as the time between the date of first documented response (CR or PR) that is subsequently confirmed, to the date of the first objectively documented tumor progression as determined by the BICR (per RECIST v1.1), or death due to any cause, whichever occurs first.
| Months | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|
| DoR Per RECISTS v1.1 by BICR in Part 2 | 8.41 (7.43 to NA) | 7.10 (5.62 to NA) |
Number of participants with an adverse event (AE). AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.
| Participants | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|
| Any Grade | 158 | 147 |
| Grade 3 to 4 | 90 | 85 |
| Grade 5 | 26 | 19 |
AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Grading will be determined for severity according to the NCI CTCAE v5.0.
| Participants | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|
| Any Grade | 147 | 138 |
| Grade 3 to 4 | 79 | 78 |
| Grade 5 | 4 | 4 |
SAE is defined as a life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe). SAEs can also result in death. The AE requires inpatient hospitalization or causes prolongation of existing hospitalization. Results in persistent or significant disability/incapacity. Is a congenital anomaly/birth defect. Is an important medical event (defined as a medical event(s) that may not be immediately lifethreatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the participant or may require intervention \[e.g., medical, surgical\] to prevent one of the other serious outcomes listed in the definition above.) Grading will be determined for severity according to the NCI CTCAE v5.0.
| Participants | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|
| Any Grade | 34 | 36 |
| Grade 3 to 4 | 26 | 28 |
| Grade 5 | 4 | 4 |
IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. Grading will be determined for severity according to the NCI CTCAE v5.0.
| Participants | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|
| Adrenal Insufficiency | 2 | 3 |
| Hypothyroidism/Thyroiditis | 22 | 13 |
| Hypothyroidism | 21 | 13 |
| Thyroiditis | 2 | 0 |
| Diabetes Mellitus | 1 | 0 |
| Hyperthyroidism | 14 | 3 |
| Hypophysitis | 0 | 1 |
Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.
Results for this outcome have not been posted.
Objective Response Rate (ORR) per RECIST v1.1 by BICR is defined as the number of participants in the randomized population who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1) divided by the number of participants in the population. BOR is defined as the best response, as determined by the BICR, recorded between the date of randomization and the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.
Results for this outcome have not been posted.
Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.
Results for this outcome have not been posted.
Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.
Results for this outcome have not been posted.
Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.
Results for this outcome have not been posted.
Progression Free Survival is defined as the time between the date of randomization and the first date of documented progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first.
Results for this outcome have not been posted.
AE is defined as any new untoward medical occurrence or worsenig of a preexising medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select Adverse Events (AEs) will be determined for severity according to the NCI CTCAE v5.0.
Results for this outcome have not been posted.
Collected over All-Cause mortality, Adverse Events and Serious Adverse Events: (From first dose to last dose + 135 days): Approximately 36 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Treatment A | 47/77 (61%) | 46/77 (59.7%) | 74/77 (96.1%) |
| Part 1: Treatment B | 46/79 (58.2%) | 52/79 (65.8%) | 78/79 (98.7%) |
| Part 2: Treatment C | 79/158 (50%) | 103/158 (65.2%) | 151/158 (95.6%) |
| Part 2: Treatment D | 70/149 (47%) | 81/149 (54.4%) | 145/149 (97.3%) |
| Event | Part 1: Treatment A | Part 1: Treatment B | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/77 | 8/79 | 40/158 | 36/149 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/77 | 7/79 | 4/158 | 7/149 |
| PneumoniaInfections and infestations | 5/77 | 6/79 | 14/158 | 10/149 |
| General physical health deteriorationGeneral disorders | 0/77 | 6/79 | 3/158 | 2/149 |
| NeutropeniaBlood and lymphatic system disorders | 1/77 | 3/79 | 4/158 | 10/149 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/77 | 3/79 | 2/158 | 1/149 |
| Atrial fibrillationCardiac disorders | 0/77 | 4/79 | 2/158 | 0/149 |
| AnaemiaBlood and lymphatic system disorders | 3/77 | 2/79 | 6/158 | 3/149 |
| COVID-19Infections and infestations | 3/77 | 0/79 | 3/158 | 0/149 |
| SepsisInfections and infestations | 3/77 | 2/79 | 0/158 | 4/149 |
| Event | Part 1: Treatment A | Part 1: Treatment B | Part 2: Treatment C | Part 2: Treatment D |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 51/77 | 43/79 | 109/158 | 92/149 |
| NauseaGastrointestinal disorders | 33/77 | 29/79 | 55/158 | 40/149 |
| FatigueGeneral disorders | 33/77 | 25/79 | 43/158 | 37/149 |
| AstheniaGeneral disorders | 30/77 | 27/79 | 37/158 | 36/149 |
| ConstipationGastrointestinal disorders | 29/77 | 17/79 | 33/158 | 20/149 |
| NeutropeniaBlood and lymphatic system disorders | 28/77 | 29/79 | 38/158 | 38/149 |
| DiarrhoeaGastrointestinal disorders | 26/77 | 18/79 | 34/158 | 30/149 |
| Decreased appetiteMetabolism and nutrition disorders | 21/77 | 24/79 | 27/158 | 34/149 |
| ThrombocytopeniaBlood and lymphatic system disorders | 14/77 | 16/79 | 47/158 | 34/149 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 20/77 | 18/79 | 15/158 | 14/149 |
| Age, Categorical(Participants) | Part 1: Treatment A | Part 1: Treatment B | Part 2: Treatment C | Part 2: Treatment D | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 37 | 42 | 73 | 72 | 224 |
| >=65 years | 42 | 38 | 85 | 79 | 244 |
| Sex: Female, Male(Participants) | Part 1: Treatment A | Part 1: Treatment B | Part 2: Treatment C | Part 2: Treatment D | Total |
|---|---|---|---|---|---|
| Female | 28 | 32 | 55 | 57 | 172 |
| Male | 51 | 48 | 103 | 94 | 296 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Treatment A | Part 1: Treatment B | Part 2: Treatment C | Part 2: Treatment D | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 16 | 12 | 31 | 28 | 87 |
| Not Hispanic or Latino | 37 | 44 | 91 | 88 | 260 |
| Unknown or Not Reported | 26 | 24 | 36 | 35 | 121 |
| Race (NIH/OMB)(Participants) | Part 1: Treatment A | Part 1: Treatment B | Part 2: Treatment C | Part 2: Treatment D | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 2 | 2 | 5 |
| White | 75 | 77 | 148 | 141 | 441 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 3 | 8 | 7 | 21 |
Showing the first 100 of 125 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Feb 2021 to primary completion in Jan 2024, 34 months.
Results were first posted in Mar 2025, 1 year 2 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 34 months is close to that.
Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Relatlimab
Carcinoma, Non-Small-Cell Lung →